Sodium polystyrene sulfonate: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 9: | Line 9: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*>1mo: 1 g/kg PO or PR q6hr PRN | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: Not absorbed systemically so infant risk minimal | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
| Line 22: | Line 23: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Hypokalemia | |||
*Obstructive bowel disease, reduced gut motility | |||
*Rectal administration in neonates, particularly if premature | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Intestinal necrosis, ulceration, perforation, fecal impaction | |||
*Bezoars | |||
===Common=== | ===Common=== | ||
*Abdominal pain, nausea/vomiting, constipation, GI disturbance | |||
*Hypokalemia | |||
*Hypocalcemia | |||
*Hypomagnesemia | |||
*Sodium retention | |||
==Pharmacology== | ==Pharmacology== | ||
| Line 32: | Line 43: | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: | ||
*Mechanism of Action: | *Mechanism of Action: Cation exchange resin, sodium ions partially released from polystyrene and replaced by potassium | ||
==See Also== | ==See Also== | ||
| Line 41: | Line 52: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:FEN]] | |||
Revision as of 22:29, 23 September 2019
General
- Type:
- Dosage Forms:
- Common Trade Names: Kayexylate
Adult Dosing
Hyperkalemia
- 30 gm oral or per rectum
Pediatric Dosing
- >1mo: 1 g/kg PO or PR q6hr PRN
Special Populations
- Pregnancy Rating: B
- Lactation: Not absorbed systemically so infant risk minimal
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
- Hypokalemia
- Obstructive bowel disease, reduced gut motility
- Rectal administration in neonates, particularly if premature
Adverse Reactions
Serious
- Intestinal necrosis, ulceration, perforation, fecal impaction
- Bezoars
Common
- Abdominal pain, nausea/vomiting, constipation, GI disturbance
- Hypokalemia
- Hypocalcemia
- Hypomagnesemia
- Sodium retention
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: Cation exchange resin, sodium ions partially released from polystyrene and replaced by potassium